UNSPSC 51433916: Forasartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C23H28N8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 065F7WPT0B, chemically known as 5-((3,5-dibutyl-1h-1,2,4-triazol-1-yl)methyl)-2-(2-(1h-tetrazol-5-ylphenyl))pyridine but generally known as forasartan, which bears US NIH Compound Identifier 132706. European Medicines Agency schedules Forasartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07781MIG.

UNSPSC 51433916 Forasartan, a Commodity code, represents pharmaceutical products—specifically branded or generic antihypertensive medications—being procured by state and local health systems, fire rescue departments, and state pharmacy benefit programs for emergency medical services, hospital formularies, and managed care distribution. State and local governments are buying these medications through competitive bidding processes tied to emergency response protocols, cooperative purchasing agreements, and state health agency pharmacy initiatives. Issuing bodies span city fire and rescue departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves sealed-bid procurement for specified medication quantities with firm pricing, supply-chain compliance, expiration-date warranties, and rapid delivery timelines, as well as participation in direct-to-manufacturer pharmacy initiatives and multi-state generic pharmaceutical contracting frameworks that coordinate with authorized pharmaceutical wholesalers.

Recent activity shows geographic spread across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026, estimated value $40,000) requiring four specific medication line items with nine-month minimum shelf life and ten-day delivery, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer prescription contracting capabilities outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by Minnesota's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across multiple state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026 and pricing weighted 75 percent on competitiveness.